RT Journal Article
T1 Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients.
A1 González-Salvatierra, Sheila
A1 García-Fontana, Cristina
A1 Andújar-Vera, Francisco
A1 Grau-Perales, Alejandro Borja
A1 Martínez-Heredia, Luis
A1 Avilés-Pérez, María Dolores
A1 Hayón-Ponce, María
A1 Iglesias-Baena, Iván
A1 Riquelme-Gallego, Blanca
A1 Muñoz-Torres, Manuel
A1 García-Fontana, Beatriz
K1 biomarker
K1 diabetic kidney disease
K1 kidney function impairment
K1 osteoglycin
K1 type 2 diabetes
AB Osteoglycin (OGN) could be a biomarker of mild kidney function impairment in type 2 diabetes (T2D). Our study aimed to determine the association between serum OGN and impaired kidney function risk in T2D patients and to analyze its potential role as an estimator of kidney disturbances in this population. This cross-sectional study included 147 T2D patients (65 ± 8 years, 58.5% males), and 75 healthy controls (63 ± 10 years, 36% males). Circulating OGN levels were determined by ELISA. Linear regression modeling was performed to determine the variables influencing circulating OGN, and an ROC curve was plotted to assess the usefulness of OGN as an estimator of diabetic kidney disease risk. Circulating OGN was significantly increased in T2D patients compared to controls (18.41 (14.45-23.27) ng/mL vs. 8.74 (7.03-12.35) ng/mL; p
SN 2077-0383
YR 2021
FD 2021-05-20
LK https://hdl.handle.net/10668/26113
UL https://hdl.handle.net/10668/26113
LA en
DS RISalud
RD Apr 12, 2025